GILD – gilead sciences, inc. (US:NASDAQ)
Stock Stats
News
Cell and Gene Therapy Investment Trends Strategic Intelligence Report 2025-2031: Yescarta from Gilead Sciences and Zolgensma from Novartis Generated $1.5 Billion and $1.2 Billion in 2024 Sales [Yahoo! Finance]
Gilead Sciences (NASDAQ:GILD) had its price target lowered by analysts at Royal Bank Of Canada from $105.00 to $100.00. They now have a "sector perform" rating on the stock.
Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $110.00 to $115.00. They now have a "neutral" rating on the stock.
Hopping Mad Over Drug Company Product Hopping [Forbes]
Gilead Sciences (NASDAQ:GILD) had its "buy" rating reaffirmed by analysts at UBS Group AG.
Form 4 GILEAD SCIENCES, INC. For: Jan 15 Filed by: Dickinson Andrew D
Form 4 GILEAD SCIENCES, INC. For: Jan 15 Filed by: Mercier Johanna
Form 144 GILEAD SCIENCES, INC. Filed by: Mercier Johanna
Form 144 GILEAD SCIENCES, INC. Filed by: Dickinson Andrew D
Form 4 GILEAD SCIENCES, INC. For: Jan 02 Filed by: Berger Dietmar
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.